Search results
Showing 736 to 750 of 1809 results for nice guidelines
Targeted-release budesonide for treating primary IgA nephropathy (TA937)
Evidence-based recommendations on targeted-release budesonide (Kinpeygo) for treating primary immunoglobulin A (IgA) nephropathy in adults.
Management of emergency department patients during the COVID-19 pandemic (Word)
contact for additional support if their condition worsens see NICE's COVID 19 rapid guideline on managing COVID 19 for...
Umesh has previous experience of developing National Guidelines for NICE as member of the Guideline...
Umesh has previous experience of developing National Guidelines for NICE as member of the Guideline...
family, as well as on children's emotional, social and cognitive development. NICE has produced guidance to reduce the risk of mental...
Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)
Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making
Axonics sacral neuromodulation system for faecal incontinence (MIB259)
NICE has developed a medtech innovation briefing (MIB) on Axonics sacral neuromodulation system for faecal incontinence .
Diabetes: blood pressure (without moderate or severe frailty) (IND249)
This indicator covers the percentage of patients with diabetes on the register, aged 79 years and under without moderate or severe frailty, in whom the last blood pressure reading (measured in the preceding 12 months) is less than 135/85 mmHg if using ambulatory or home monitoring, or less than 140/90 mmHg if measured in clinic. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM233
This indicator covers the percentage of adults and young people at a GP surgery in an area of high or extremely high HIV prevalence who have not had an HIV test in the last 12 months, who are having a blood test and receive an HIV test at the same time. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM190
This indicator covers the percentage of adults and young people newly registered with a GP in an area of high or extremely high HIV prevalence who receive an HIV test within 3 months of registration. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM189
High-throughput non-invasive prenatal testing for fetal RHD genotype (DG25)
Evidence-based recommendations on high-throughput non-invasive prenatal testing (NIPT) for fetal RHD genotype
Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)
Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making
In development [GID-TA11408] Expected publication date: TBC
The NICE glossary provides brief definitions and explanations of terms used on the website. The terms describe how NICE works and how its guidance is produced.
Biographies and interests register for the indicator advisory committee